for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BIOTON SA

BIOP.WA

Latest Trade

4.48PLN

Change

-0.16(-3.35%)

Volume

17,510

Today's Range

4.48

 - 

4.69

52 Week Range

3.88

 - 

6.50

As of on the Warsaw Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
4.63
Open
4.67
Volume
17,510
3M AVG Volume
1.01
Today's High
4.69
Today's Low
4.48
52 Week High
6.50
52 Week Low
3.88
Shares Out (MIL)
85.86
Market Cap (MIL)
370.07
Forward P/E
--
Dividend (Yield %)
--

Next Event

Bioton SA Annual Shareholders Meeting

Latest Developments

More

Bioton Q2 Net Result Turns To Loss Of 87.5 Mln Zlotys

Bioton Books Impairment Loss To Affect Its H1 Net Result

Bioton Says Biomm Terminates Deal For Commercialization Of Recombinant Human Insulin In Brazil

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About BIOTON SA

Bioton SA is a Poland-based company active in the pharmaceutical sector. The Company is engaged in research, development and wholesale trade of pharmaceutical and biotechnological products. The Company's portfolio consists of oral hypoglycemic drugs (metformin and glimepride) as well as recombinant human insulin in pharmaceutical substance form and for injections. Additionally, the Company provides advertising services. As of December 31, 2011, the Company formed a capital group and operated through its subsidiaries, including BIOTON TRADE Sp. z o.o., Mindar Holdings Ltd, Germonta Holdings Ltd, Tricel SA, SciGen Ltd and BioPartners Holdings AG, among others. On June 12, 2014, it sold a 50% stake in Copernicus Sp. z o.o.

Industry

Biotechnology & Drugs

Contact Info

ul. Staroscinska 5

+48.22.7214000

http://www.bioton.pl

Executive Leadership

Jubo Liu

Chairman of the Supervisory Board

Robert Neymann

Chairman of the Management Board

Dariusz Trzeciak

Vice Chairman of the Supervisory Board

Vaidyanathan Viswanath

Vice Chairman of the Supervisory Board

Adam Tomasz Polonek

Member of the Management Board

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
1.94
Price To Book (MRQ)
0.59
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
23.33
LT Debt To Equity (MRQ)
9.70
Return on Investment (TTM)
-15.03
Return on Equity (TTM)
-12.13

Latest News

Latest News

BRIEF-Bioton Q2 Net Result Turns To Loss Of 87.5 Mln Zlotys

* REPORTED ON MONDAY Q2 NET LOSS OF 87.5 MILLION ZLOTYS VERSUS PROFIT OF 66.3 MILLION ZLOTYS YEAR AGO

BRIEF-Bioton Says China-Based Harbin Gloria Pharmaceuticals Terminates Distribution Deal

* SAID ON FRIDAY THAT HARBIN GLORIA PHARMACEUTICALS HAS TERMINATED DEAL FOR SUPPLY AND DISTRIBUTION OF BIOTON'S INSULIN PRODUCTS ON CHINESE MARKET

BRIEF-Bioton Q2 Net Result Turns To Profit Of 66.1 Mln Zlotys

* REPORTED ON THURSDAY Q2 NET PROFIT OF 66.1 MLN ZLOTYS VS LOSS OF 0.4 MLN ZLOTYS YEAR AGO

BRIEF-Bioton Signs Cooperation Agreement With Sequoia

* SAID ON THURSDAY THAT IT HAS SIGNED A COOPERATION AGREEMENT WITH SEQUOIA SP. Z O.O. (SEQUOIA) REGARDING PRODUCTION, DISTRIBUTION AND PROMOTION OF PRODUCTS

BRIEF-Bioton Q1 BNet Result Turns To Profit of 2.2 Mln Zlotys

* REPORTED ON WEDNESDAY Q1 NET PROFIT 2.2 MILLION ZLOTYS VS LOSS OF 10.8 MILLION ZLOTYS YR AGO

BRIEF-Bioton FY Net Loss Narrows To 7.3 Mln Zlotys

* REPORTED ON FRIDAY FY NET LOSS OF 7.3 MILLION ZLOTYS VERSUS LOSS OF 28.6 MILLION ZLOTYS YEAR AGO

BRIEF-Biomed Lublin Signs Cooperation Agreement With Bioton

* SIGNS COOPERATION AGREEMENT WITH BIOTON SA ON MARKETING CO'S PRODUCT DISTREPTAZA

BRIEF-Bioton To Continue As Going Concern

* SAID ON FRIDAY THAT ITS SHAREHOLDERS RESOLVED THAT THE COMPANY WILL CONTINUE AS A GOING CONCERN

BRIEF-Bioton Seeks For Investor For Its Unit SciGen

* STARTS SEARCHING FOR INVESTOR WHICH WOULD BE WILLING TO ACQUIRE CO'S STAKE IN SCIGEN LTD Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-BIOTON Closes Sale Of Tricel

* SAID ON SUNDAY THAT IT CLOSED TRANSACTION OF SELLING 100% STAKE OF ITS UNIT TRICEL TO MEDWISE PHARMACEUTICALS LIMITED BASED IN CANADA

BRIEF-Bioton Q3 net loss narrows to 1.5 mln zlotys

* Q3 NET LOSS AT 1.5 MILLION ZLOTYS VERSUS LOSS OF 2.9 MILLION ZLOTYS YEAR AGO

BRIEF-Bioton H1 net loss widens to 11.2 mln zlotys

* H1 REVENUE 178.8 MILLION ZLOTYS VERSUS 182.2 MILLION ZLOTYS YEAR AGO

BRIEF-Bioton Q1 net result turns to loss of 10.8 mln ​zlotys

* REPORTED ON TUESDAY THAT ITS Q1 REVENUE WAS 87.8 MILLION ZLOTYS VERSUS 84.4 MILLION ZLOTYS A YEAR AGO

BRIEF-Robert Neymann new CEO and Jubo Liu new chairman of supervisory board of Bioton

* SAID ON MONDAY THAT ROBERT NEYMANN HAS BEEN APPOINTED A NEW CEO OF THE COMPANY

BRIEF-Bioton FY net loss shrinks to 28.6 mln zlotys yoy

* Said on Monday that its FY 2016 revenue was 347.8 million zlotys ($71.04 million) versus 404.4 million zlotys a year ago

BRIEF-Bioton signs prelim. agreement to sell Tricel

* Said on Saturday that on April 10 it signed a preliminary agreement to sell Luxembourg-based Tricel SA to Canada-based Medwise Pharmaceuticals Limited (Medwise) for no more than 3.3 million euros ($3.59 million)

BRIEF-CFI Holding excluded from sWIG80 index as of March 18

* CFI Holding Said on Friday that as a result of the changes in the composition of the Warsaw Stock Exchange indices, as of March 18 its shares would no longer be included into the sWIG80 index

BRIEF-Bioton appoints new CEO, chairman of supervisory board

* Said on Friday that Jubo Liu has been appointed the company's new CEO as of Nov. 26

BRIEF-Bioton Q3 net result turns to loss of 2.9 mln zlotys YOY

* Reported on Friday its Q3 revenue of 89.1 million zlotys ($21.47 million) versus 112.7 million zlotys a year ago

BRIEF-Bioton gets 10-yr permit to sell preparation in EU

* Said on Wednesday that its unit, Biolek sp. z o.o., receives information from the European Commission about issuing a permit allowing sales of Suilectin preparation in the whole European Union

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up